Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05668741 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
A Phase 1 study of Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
- 20
- Study locations
NCT05668741 is a Phase 1 study of Cystic Fibrosis that is actively recruiting participants, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 39 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT05668741, a Phase 1 study of Cystic Fibrosis, is actively recruiting participants, sponsored by Vertex Pharmaceuticals Incorporated.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, and tolerability and efficacy of VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic fibrosis transmembrane conductance regulator (CFTR) genotype not responsive to CFTR modulator therapy.
Conditions Studied
Interventions
- DRUG VX-522 mRNA therapy
- DRUG IVA
Study Locations (20)
Ohio
- UC Health Holmes Hospital - Cincinnati
- UH Cleveland Medical Center - Pulmonology - Cleveland
- Nationwide Children's Hospital - Columbus
California
- Memorial Health Services on behalf of Long Beach Memorial Medical Center d/b/a Miller Children's Hospital Long Beach - Long Beach
- Stanford University - Palo Alto - Pulmonology - Palo Alto
Maryland
- PAREXEL International - Baltimore - Baltimore
- The Johns Hopkins University - Johns Hopkins Hospital - Pulmonology - Baltimore
Massachusetts
- MGH - MGfC Pediatric Cystic Fibrosis Center - Boston
- Boston Children's Hospital - Boston
New York
- Medicine at East 85th Street - New York
- Presbyterian Hospital - Pulmonology - New York
Alabama
- University of Alabama at Birmingham - Child Health Research Unit - Birmingham
Colorado
- National Jewish Health - Denver
Florida
- Shands Hospital - Pulmonology - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2023-02-27 |
| Est. Completion | 2027-05-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05668741
The ClinicalTrials.gov registry entry for NCT05668741 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (78% lower). The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which VX-522 mRNA therapy is the first listed.
NCT05668741 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Ohio, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT05668741 about?
NCT05668741 is a clinical study titled "A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)". The purpose of this study is to evaluate the safety, and tolerability and efficacy of VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic fibrosis transmembrane conductance regulator (CFTR) genotype not responsive to CFTR modulator therapy.
What is the current status of trial NCT05668741?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2023-02-27. Estimated completion is 2027-05-12.
What conditions does trial NCT05668741 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
What interventions are being tested in trial NCT05668741?
The interventions under investigation include: VX-522 mRNA therapy (DRUG), IVA (DRUG).
Who is sponsoring clinical trial NCT05668741?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05668741 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
RECRUITING · Phase 1
-
A Study Assessing KB407 for the Treatment of Cystic Fibrosis
RECRUITING · Phase 1
-
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants
RECRUITING · Phase 1
-
A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)
RECRUITING · Phase 1
-
Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
RECRUITING · Phase 1
-
Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.